ATI-2341 TFA

• CAT Number: I046097
• Molecular Formula: C106H179F3N26O27S2
• Molecular Weight: 2370.84
• Purity: ≥95%
• Synonyms: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-(hexadecanoylamino)-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoic acid;2,2,2-trifluoroacetic acid

ATI-2341 TFA（Cat No.:I046097）is a synthetic peptide agonist of the chemokine receptor CXCR4, a G protein-coupled receptor involved in immune cell trafficking, cancer metastasis, and HIV infection. By mimicking natural CXCR4 ligands, ATI-2341 activates receptor signaling, enabling researchers to investigate CXCR4-mediated pathways, receptor desensitization, and internalization. The trifluoroacetate (TFA) salt enhances peptide solubility and stability, making it well-suited for in vitro and in vivo studies. ATI-2341 TFA serves as a valuable pharmacological probe in immunology, oncology, and virology research, supporting drug discovery targeting CXCR4-associated diseases.